| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup …
Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $0 and sold $0 worth of Gossamer Bio, Inc. stock.
On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $442,157 and sold $284,358 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 26,050 shares for transaction amount of $50,016 was made by Milligan Sandra (director) on 2025‑08‑19.
| 2025-08-19 | Milligan Sandra | director | 26,050 0.0115% | $1.92 | $50,016 | +8.85% | ||
| 2024-06-24 | Sale | Aranda Richard | Chief Medical Officer | 1,908 0.0007% | $0.66 | $1,260 | +16.58% | |
| 2024-06-21 | Hasnain Faheem | President & CEO | 372,000 0.2168% | $0.67 | $250,282 | +48.00% | ||
| 2024-06-18 | Giraudo Bryan | COO/CFO | 100,000 0.0512% | $0.59 | $59,110 | +77.24% | ||
| 2024-06-17 | Smith Robert Paul JR | Chief Commercial Officer | 25,000 0.013% | $0.60 | $15,050 | +84.64% | ||
| 2024-03-27 | Sale | Christian Waage | EVP, Tech Ops and Admin | 6,430 0.0028% | $1.16 | $7,430 | -22.01% | |
| 2024-03-27 | Sale | Hasnain Faheem | President & CEO | 23,172 0.0101% | $1.16 | $26,773 | -22.01% | |
| 2024-03-27 | Sale | Giraudo Bryan | COO/CFO | 6,430 0.0028% | $1.16 | $7,431 | -22.01% | |
| 2024-03-18 | Sale | Aranda Richard | Chief Medical Officer | 4,018 0.0017% | $1.33 | $5,342 | -33.88% | |
| 2024-03-18 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 4,018 0.0017% | $1.33 | $5,343 | -33.88% | |
| 2023-11-15 | Milligan Sandra | director | 32,000 0.0139% | $0.79 | $25,213 | +11.06% | ||
| 2023-11-13 | Giraudo Bryan | COO/CFO | 200,000 0.0795% | $0.56 | $112,880 | +42.98% | ||
| 2023-06-22 | Sale | Aranda Richard | Chief Medical Officer | 1,814 0.0018% | $1.29 | $2,340 | -34.61% | |
| 2023-04-04 | Giraudo Bryan | COO/CFO | 55,000 0.0583% | $1.02 | $56,095 | +3.96% | ||
| 2023-03-16 | Sale | Aranda Richard | Chief Medical Officer | 7,563 0.0083% | $1.10 | $8,304 | 0.00% | |
| 2023-03-16 | Sale | Carter Laura | Chief Scientific Officer | 6,029 0.0066% | $1.10 | $6,620 | 0.00% | |
| 2023-03-16 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 7,564 0.0083% | $1.10 | $8,305 | 0.00% | |
| 2022-10-24 | Sale | Aranda Richard | Chief Medical Officer | 4,757 0.0056% | $12.07 | $57,431 | -88.98% | |
| 2022-10-24 | Sale | Carter Laura | Chief Scientific Officer | 4,876 0.0058% | $12.07 | $58,868 | -88.98% | |
| 2022-10-24 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 4,757 0.0056% | $12.07 | $57,431 | -88.98% |
| Hasnain Faheem | President & CEO | 5408073 88.5034% | $50.19M | 4 | 2 | +8.78% |
| Gujrathi Sheila | President & CEO | 4048242 66.2497% | $37.57M | 1 | 0 | <0.0001% |
| Christian Waage | EVP, Tech Ops and Admin | 585934 9.5888% | $5.44M | 4 | 3 | <0.0001% |
| Giraudo Bryan | COO/CFO | 480010 7.8554% | $4.45M | 9 | 3 | +10.16% |
| Carter Laura | Chief Scientific Officer | 76263 1.248% | $707,720.64 | 1 | 6 | |
| Milligan Sandra | director | 58050 0.95% | $538,704.00 | 2 | 0 | +9.96% |
| Smith Robert Paul JR | Chief Commercial Officer | 25000 0.4091% | $232,000.00 | 1 | 0 | +84.64% |
| Cox Russell J. | director | 7200 0.1178% | $66,816.00 | 1 | 0 | +6.27% |
$5,831,763 | 118 | -33.78% | $66.68M | |
$17,525,882 | 60 | 5.22% | $64.7M | |
$103,288,323 | 51 | 4.78% | $56.52M | |
$19,705,388 | 47 | 86.26% | $67.15M | |
$909,129 | 37 | 42.19% | $67.23M |
| Increased Positions | 121 | +76.58% | 31M | +17.04% |
| Decreased Positions | 65 | -41.14% | 26M | -14.33% |
| New Positions | 52 | New | 6M | New |
| Sold Out Positions | 16 | Sold Out | 5M | Sold Out |
| Total Postitions | 214 | +35.44% | 186M | +2.71% |
| Nea Management Company, Llc | $52,108.00 | 7.83% | 18.09M | 0 | 0% | 2025-09-30 |
| Octagon Capital Advisors Lp | $49,104.00 | 7.38% | 17.05M | -1M | -7.08% | 2025-09-30 |
| Blackrock, Inc. | $39,877.00 | 5.99% | 13.85M | +2M | +14.03% | 2025-09-30 |
| Vanguard Group Inc | $34,588.00 | 5.2% | 12.01M | +598,981 | +5.25% | 2025-09-30 |
| Arch Venture Management, Llc | $23,201.00 | 3.49% | 8.06M | 0 | 0% | 2025-09-30 |
| Samsara Biocapital, Llc | $17,655.00 | 2.65% | 6.13M | 0 | 0% | 2025-09-30 |
| Palo Alto Investors Lp | $15,737.00 | 2.37% | 5.46M | -274,664 | -4.79% | 2025-09-30 |
| Siren, L.L.C. | $15,002.00 | 2.26% | 5.21M | 0 | 0% | 2025-09-30 |
| 683 Capital Management, Llc | $14,570.00 | 2.19% | 5.06M | -1M | -20.2% | 2025-09-30 |
| Acadian Asset Management Llc | $14,437.00 | 2.17% | 5.01M | -2M | -29.85% | 2025-09-30 |